Kornimate/medical-research-clean huggingface dataset:
study of electrophysiological markers related to the cognitive and affective processes behind empathic behaviour in schizophrenic spectrum disorder

Conditions: Schizophrenia

Summary: disorders of social cognition, and empathy more specifically, are at the heart of schizophrenic pathology in that they are strongly linked to the social handicap of patients. it is therefore necessary to refine our knowledge of the cognitive and affective processes behind this empathic disorder and to identify objective and easily measurable markers (related to brain functioning collected by electroencephalography) of these processes with the subsequent aim of improving their management. it is also relevant to question the trait/status nature of these empathic disorders by studying these markers in individuals presenting more or less marked schizotypic traits and therefore more or less at risk of developing schizophrenia. studying the possibility that empathy disorders may be part of the factors of developmental vulnerability for schizophrenia and identifying objective markers of this vulnerability could allow, in case of development of the pathology, a more rapid diagnosis and a more effective management.


Eligibility criteria:
inclusion criteria: * common to all: good command of the french language, right-handed. * specific to patients: diagnosis of schizophrenia or schizoaffective disorder, clinical state stabilized according to the treating psychiatrist. exclusion criteria: * common to all: having suffered a head injury with loss of consciousness lasting more than 5 minutes, participating in another project at the time of the present study, presenting an addiction to a toxic substance (excluding tobacco), presenting a mental retardation or neurological disorder (verified by a pre-recruitment interview and the administration of the mini international neuropsychiatric interview for control subjects and on the basis of the information in the medical file for patients). * patient-specific: significant change (according to the doctor) in treatment in the previous month, currently hospitalized. * specific to controls: taking a psychoactive drug, having a mental disorder, being first-degree related to a patient with a disorder other than schizophrenia or schizoaffective disorder.
risk factors for refeeding syndrome in the surgical intensive care unit

Conditions: Refeeding Syndrome

Summary: refeeding syndrome is a condition that occurs when patients who are undernourished or undernourished suddenly start overfeeding, causing electrolyte disturbances and vitamin deficiencies, resulting in neurological and cardiac problems. it may even result in death. it is aimed to prevent the development of refeeding syndrome with nutrition in accordance with the guidelines. the aim of this study is to determine the risk factors for refeeding syndrome in intensive care unit (icu).

nutritional support is an important part of treatment in intensive care patients. especially existing comorbidities and developing acute problems before intensive care admission can cause serious malnutrition for patients. refeeding syndrome is a serious, life-threatening condition accompanied by electrolyte and metabolic disorders as a result of rapid re-feeding following prolonged starvation or malnutrition. the condition may be accompanied by electrolyte disorders such as hypophosphatemia, hypokalemia and hypomagnesemia, as well as decrease in vitamin levels (especially vitamin b1), fluid imbalance and salt retention. the resulting imbalances can cause cardiac and neurological side effects, impaired organ functions and even death. the refeeding protocol should be individualized to each patient's clinical situation. in this study, although nutritional protocols in accordance with the guidelines are applied in patients with risk factors for the development of refeeding syndrome, whether refeeding syndrome develops and the facilitating factors will be investigated in icu.

Eligibility criteria:
inclusion criteria: 1. patients are intensive care patients 2. patients' age \> 18 - exclusion criteria: 1. diabetic ketoacidosis 2. other risk factors for hypophosphatemia (patients on continuous hemodialysis, hyperphosphatemia treatment, parathyroidectomy) 3. patients with pre-study hypophosphatemia (\< 0.65 mmol/l) 4. patients with hyperparathyroidism 5. terminal stage cancer patients 6. patients with glasgow coma scale ≤5 7. patients with respiratory and metabolic alkalosis -

Keywords: hypophosphatemia hypomagnesemia
the effect of exercise practices on hyperactivity levels in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder; Autism

Summary: the aim of this study is to examine the effect of vestibular and proprioceptive exercise practices on the hyperactivity level in children with autism spectrum disorder.

the families of all children participating in the study will be informed and their written consent will be obtained. vestibular and proprioceptive evaluation, hyperactivity evaluation and nystagmus evaluation will be applied to each child participating in the study twice, before and after treatment. children will be divided into two groups: an exercise group and a control group, consisting of equal numbers of patients. a classical physical therapy program will be applied to both groups. in addition to the exercise group, a treatment program including vestibular and proprioceptive exercise training will be applied. the training program for both groups will be held in 40-minute sessions, 2 days a week for 8 weeks.

Eligibility criteria:
inclusion criteria: * children whose voluntary consent form is signed by their parents * children ages 6 to 10 * not using supplements * not having undergone any surgical operation exclusion criteria: * children who have any obstacle to exercise * they were determined as children who could not cooperate in the study.
a study to evaluate the effectiveness of aranesp® for cancer patients with anemia

Conditions: Anemia; Neoplasms

Summary: the purpose of this trial is to assess the effectiveness of aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and maintaining hemoglobin levels consistent with the national comprehensive cancer network (nccn) guidelines).


Eligibility criteria:
inclusion criteria: - subjects with non-myeloid malignancy - anemia (hgb less than 11.0 g/dl) due to cancer chemotherapy - receiving chemotherapy and expected to receive at least 8 additional weeks of chemotherapy - adequate renal function - adequate liver function exclusion criteria: - subjects with acute myelogenous leukemia (aml), chronic myelogenous leukemia (cml), or myelodysplastic syndromes (mds) - unstable cardiac disease - active bleeding - active systemic or chronic infection - severe active chronic inflammatory disease - other hematologic disorder associated with anemia - uncontrolled hypertension - known iron or nutritional deficiency - known positive test for human immunodeficiency virus (hiv) infection - history of pure red cell aplasia - history of positive antibody response to any erythropoietic agent - erythropoietin therapy within 4 weeks before screening - rbc transfusions within 2 weeks prior to screening

Keywords: anemia fatigue aranesp® clinical trial
optical coherence tomography-based positioning for macular hole surgery

Conditions: Macular Hole Surgery

Summary: the efficacy of macular hole (mh) surgery with the halting of prone positioning by monitoring the mh closure in the swept source optical coherence tomographic (ss-oct) images was compared with the surgery by the surgeon's decision. the macular hole closure and visual outcome were compared.

the efficacy of macular hole (mh) surgery with the halting of prone positioning by monitoring the mh closure in the swept source optical coherence tomographic (ss-oct) images was compared with the surgery by the surgeon's decision. all eyes were treated by pars plana vitrectomy, internal limiting membrane peeling, and gas tamponade. mh closure was defined as a connection of the edges of the sensory retina in the ss-oct images.the macular hole closure and visual outcome were compared.

Eligibility criteria:
inclusion criteria: * the patients were followed more than 2 months. exclusion criteria: * eye with axial length more than 26.0 mm
study to assess the safety and effectiveness of nmra-335140-501

Conditions: Major Depressive Disorder

Summary: this is a 52-week open-label extension (ole) study that will evaluate the safety, tolerability, and effectiveness of nmra-335140 in participants with major depressive disorder (mdd). participants who completed a parent study investigating the efficacy and safety of nmra-335140 as a treatment for mdd (ie, nmra-335140-301, nmra-335140-302, or nmra-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.


Eligibility criteria:
key inclusion criteria: rollover participants are eligible for the study if the following inclusion criteria are met: * completed a previous nmra-335140 phase 3 mdd study (example: nmra-335140-301, nmra-335140-302, or nmra-335140-303) according to the completion definition in the parent study protocol. * signed an informed consent form (icf) for this study. * willing to comply with the contraception requirements described in the inclusion criteria of the parent study protocol. * willing to comply with the concomitant medication/therapy restrictions described in the exclusion criteria of the parent study protocol. key exclusion criteria: rollover participants are excluded from the study if any of the following exclusion criteria are met: * diagnosed with another diagnostic and statistical manual of mental disorders, fifth edition, text revision (dsm-5-tr) disorder that would have been exclusionary in the parent study (eg, personality disorder, bipolar 1 or 2, schizophrenia, any other psychotic disorder, or moderate or severe substance or alcohol use disorder \[excluding nicotine\]). * considered to be at significant risk of suicide in the judgment of the investigator. this includes participants who are actively suicidal (eg, any suicide attempts during the parent study) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the c-ssrs ("since last visit" version, score of "yes" on suicidal ideation item 4 or 5) and/or based on clinical evaluation by the investigator; or are homicidal, in the opinion of the investigator. * non-adherent with study medication (took ≤70% of study drug over any 2-week visit interval) or procedures during the parent study. * experienced treatment emergent adverse events (teaes) considered related to the study medication from the parent study and judged by the investigator to be clinically significant to render the participant ineligible for enrollment. * have an abnormality on ocular examination that would prohibit continued study participation as determined by the investigator. * use of disallowed concomitant medication or therapy that would have been exclusionary in the parent study, may compromise the safety of the participant, and/or confound the interpretation of protocol assessments. * considered by the investigator to be inappropriate for any other reason.

Keywords: major depressive disorder nmra-335140 long-term safety efficacy navacaprant nmra335140 nmra 335140
long-term impact in intensive care survivors of coronavirus disease (covid-19)

Conditions: COVID-19

Summary: the investigator seeks to evaluate the long term neurological and pulmonary sequelae of covid-19.

recent data suggests that survivors of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) or (covid-19) report adverse health status, including neurological and cognitive deficits and impaired pulmonary function, even months after discharge. adult covid-19 survivors after icu stay, who are noted to have increased mortality and organ failure, are at higher risk of long-term disabilities and impaired quality of life. this study is one branch of a multi-site study coordinated by gilead sciences, in which participants who were critically ill with covid-19 will be followed at three and nine months after discharge to test pulmonary function, cognitive function, and quality of life.

Eligibility criteria:
inclusion criteria: * clinically suspected or laboratory confirmed covid-19 infection by real-time pcr * admission to an intensive care unit for covid-19 and discharge exclusion criteria: * pregnancy * participants unable to complete long-term follow-up due to logistical problems * participant paralyzed before being admitted to hospital for covid-19 * history of pulmonary resection * previous pulmonary transplant * documented advanced neurologic order for which the patient is unable to carry out 6 minute walk test * documented psychiatric disease for which the patient is unable to carry out interview
evla and optimal timing of sclerotherapy

Conditions: Venous Reflux

Summary: the aim of the study is to investigate the optimal timing of sclerotherapy for treatment of varicose tributaries on evla (endogenous laser ablation) patients.

the study inclusion criteria is patients with main trunk (vsm, ssv, aasv) reflux to be treated with evla, suffering c2-c3 varicose disease, age 18-years and no severe co-morbidities. patients with written consent will be randomized to two primary treatments groups; evla only and evla combined with sclerotherapy of varicose tributaries. the primary outcome is the requirement additional sclerotherapy on 3 month control visit. other study outcomes are pain, quality of life (veins questionnaire), severity score and also recurring of varicose disease at 1, 3 and 5 years.

Eligibility criteria:
inclusion criteria: * varicose disease of lower extremity caused by reflux of vsm, ssv or aasv to be treated with evla. age over 18 years. clinical symptoms c2-3. exclusion criteria: * no severe comorbidities. previous dvt.
evaluation of postural effects on multiple-breath-washout derived lung function parameters

Conditions: Pulmonary Healthy Controls; Pulmonary Disease

Summary: the investigators aim to evaluated the effect of postural changes on novel lung function parameters derived from multiple-breath-washout.


Eligibility criteria:
inclusion criteria: * patients with and without known pulmonary disease exclusion criteria: * pregnancy * inability to participate
dynact in preoperative imaging before insertion of stentgraft

Conditions: Abdominal Aortic Aneurysm

Summary: endovascular therapy of aortic aneurysms depends on good imaging facilities. a relatively new kind of x-ray equipment makes it possible to create computer tomography (ct) - like slice images in the operating room. the purpose of this study is to verify the clinical usefulness of dynact in a preoperative setting. to do so we compare aortic measurements in dynact to the same measurements in ordinary ct-images which are regarded the gold standard.


Eligibility criteria:
inclusion criteria: * not inserted stent graft before. * patiens over 60 years old. * able to give informed consent. exclusion criteria: not -

Keywords: evar dynact
non-interventional, retrospective cohort study to explore antidepressant treatment in korea

Conditions: Major Depression

Summary: the primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit of antidepressant therapy in real-world practice.

while there are many antidepressants from which physicians can select based on efficacy and tolerability profile, evidence on effectiveness and safety outcomes of new antidepressants in real clinical practice among korean mdd population is limited. hence, this study will explore the following primary, secondary objectives using national health insurance database : 1. explore baseline characteristics and drug utilization patterns of 11 commonly used antidepressant therapy during 90 days of acute treatment phase 2. explore drug utilization patterns such as therapy changes, medication compliance and recurrence relationship, and risk of adverse outcomes during maintenance phase 3. choice of antidepressants and drug utilization patterns in patients with various comorbidities 4. the relationship of non-pharmacologic treatment and discontinuation, medication compliance 5. choice of antidepressants by non-psychiatric specialty

Eligibility criteria:
inclusion criteria patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. patients aged 18 years or older on the index date 2. patients who had at least one inpatient claim or two outpatient claims in the intake period with any of the following diagnosis codes f06.3 organic mood \[affective\] disorders f32\* depressive episode f33\* recurrent depressive disorder f34.1 neurotic depression f38.1 other recurrent mood \[affective\] disorder f41.2 mixed anxiety and depressive disorder 3. patients prescribed any of the following antidepressant during intake period (from january 1, 2017 to june 30, 2018) exclusion criteria patients meeting any of the following criteria will not be included in the study: 1. patients with a claim of diagnosis codes in table 1 during the 12 month pre-index period 2. patients with a claim of prescription in table 2 during the 12 month pre-index period 3. patient who had a claim as a beneficiary of medical aid program (korean medicaid program with free or minimum copay) 4. patients who are hospitalized at the index date 5. patients who are under hospice care (procedure codes wg\*-wo\*)
factor xa inhibitor for prevention of venous thromboembolism in patients undergoing elective total knee replacement

Conditions: Thromboembolism

Summary: evaluate the safety and tolerability of escalating oral doses of ym150 in patients undergoing elective primary total knee replacement surgery


Eligibility criteria:
inclusion criteria: * scheduled for elective primary total knee replacement surgery * legal minimum age requirement ( country-specific) * written informed consent has been obtained exclusion criteria: * documented history or considered to be at increased risk of venous thromboembolism * subjects considered to be at increased risk of bleeding: * known hemorrhagic disorder and/or coagulation disorder * thrombocytopenia * clinically important bleeding occurred within 3 months prior to the screening visit * acute bacterial endocarditis * severe hypertension * retinopathy * concomitant use of anticoagulants / antiplatelet agents (including homeopathic drugs) and/or anticipated postoperative need for other reasons than prevention of dvt during the study period.

Keywords: factor xa inhibitor thromboembolism arthroplasty knee replacement prevention and control
the effects of cardiac rehabilitation on sleep quality and sleep duration in patients after coronary artery bypass graft

Conditions: Coronary Artery Disease; Coronary Artery Bypass Graft; Sleep Quality; Cardiac Rehabilitation

Summary: this study aims to investigate the effects of cardiac rehabilitation on sleep quality and sleep duration in patients after coronary artery bypass graft.

coronary artery disease (cad) is one of the common cardiovascular diseases, including myocardial infarction and unstable angina pectoris. using the global burden of disease statistical data analysis in 2020, khan and other scholars found that the global prevalence of cad is about 1,655 per 100,000 people, and the prevalence rate in taiwan is about 1759 per 100,000 people, slightly higher than the global prevalence rate. therefore, all countries in the world attach great importance to the prevention and treatment of cad. in addition to common risk factors such as age, metabolic disease, smoking, and poor lifestyle habits such as insufficient physical activity, the literature indicates that sleep quality and sleep duration are also significantly associated with cad. a 2011 meta-analysis by francesco et al. pointed out that people who sleep less than 5 hours have a higher risk of cad and are significantly associated with higher mortality rate. patients with cad who self-reported poor sleep quality and short sleep duration still had a high proportion after heart-related treatment. in 1993, redeker tracked the related symptoms of patients after coronary artery bypass graft(cabg) and found that the sleep disturbance of patients did not improve, but increased. a systematic review of the literature by liao et al. also found similar results. the sleep quality and sleep duration of patients after cabg can be improved over time, but a high proportion of patients still complain of sleep disturbance. therefore, the influence of sleep disturbance in patients with cad will persist, and studies have also suggested that persistent sleep disturbance will increase the readmission rate and mortality rate of patients with cad. therefore, it is very important to actively manage the sleep quality and sleep time of patients with cad.

Eligibility criteria:
inclusion criteria: * age between 40-80 years old * have undergone cabg * the score of psqi \> 5 * can accomplish with instructions and complete the evaluation process * body mass index less than 35 kg/m2 exclusion criteria: * diagnosed with * sleep apnea (e.g., obstructive sleep apnea, and central sleep apnea) * drug or alcohol dependence * psychology disease * neurological or musculoskeletal disorders that may interfere with cr * uncontrolled cardiac status (e.g., unstable angina, and uncontrolled arrhythmia) * women in pregnancy

Keywords: coronary artery disease coronary artery bypass graft sleep quality sleep duration cardiac rehabilitation
probiotic supplementation on weight loss

Conditions: Bariatric Surgery Candidate

Summary: the investigators are trying to better understand how bariatric surgery leads to weight loss, and the role of bacteria that live in the gut in making this happen.

the investigators are interested in seeing how a probiotic, which is a dietary supplement containing large amounts of 'good' bacteria, can influence the make-up of the gut bacterial population and what effect it has on weight loss and loss of fat. before undergoing weight loss surgery (sleeve gastrectomy or roux-en-y gastric bypass), study participants will be asked to provide a stool sample to assess the make-up of their gut bacterial population. they will also undergo a limited ct scan of the abdomen and dexa (xray) to help assess the amount of fat present inside the body. after undergoing weight loss surgery (sleeve gastrectomy or roux-en-y gastric bypass), study participants will be given either a probiotic supplement or dummy pill (placebo) for 3 months, in addition to all usual care that occurs after surgery. the ct scan, dexa scan and stool sample will be repeated at the end of the 3 month period and analyzed for changes.

Eligibility criteria:
inclusion criteria: 1. all subjects who are \> 18 and \< 65 years of age recruited from the mayo clinic bariatric surgery clinic 2. will also meet one of the national institute of health's criteria for bariatric surgery, i.e. body mass index (bmi) \> 40 kg/m2 or bmi \> 35 kg/m2 with significant weight-related comorbidities. 3. patients will be eligible if they are not on chronic antibiotic therapy and without active systemic illness. exclusion criteria: 1. patients with type 1 or 2 diabetes will be excluded due to the known pre-existing changes in the gut microbiome in this population. all patients will not have had exposure to probiotics, prebiotics or antibiotics in the preceding 4 weeks. 2. patients with allergy to antibiotics precluding the use of standard peri-operative antibiotics (cefazolin and metronidazole) will be excluded.

Keywords: probiotic microbiome